Winnow Wealth LLC Raises Stock Holdings in Elanco Animal Health Incorporated $ELAN

Winnow Wealth LLC grew its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 271,064.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,963 shares of the company’s stock after acquiring an additional 37,949 shares during the quarter. Winnow Wealth LLC’s holdings in Elanco Animal Health were worth $873,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Elanco Animal Health in the first quarter valued at $2,065,000. Goldman Sachs Group Inc. lifted its position in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares during the period. Empowered Funds LLC lifted its position in Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after buying an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after buying an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in Elanco Animal Health by 2,006.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after buying an additional 295,651 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Price Performance

ELAN stock opened at $23.67 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. Elanco Animal Health Incorporated has a 1 year low of $13.15 and a 1 year high of $27.72. The firm has a market cap of $11.82 billion, a P/E ratio of -47.34, a price-to-earnings-growth ratio of 1.55 and a beta of 1.69. The stock has a 50-day simple moving average of $22.86 and a 200-day simple moving average of $23.42.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the firm earned $0.37 earnings per share. The company’s revenue for the quarter was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts predict that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction dated Friday, May 15th. The stock was acquired at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rajeev A. Modi bought 4,911 shares of the stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. increased their target price on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. KeyCorp increased their target price on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, Citigroup increased their target price on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and a consensus price target of $28.20.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.